NCCN Recommends TTFields With Temozolomide for Newly Diagnosed GBM

March 20, 2018 – The NCCN has added the combination of TTFields and temozolomide to its guidelines for Category 1 treatment of newly diagnosed glioblastoma following maximal safe resection and completion of radiation therapy. TTFields is an antimitotic treatment modality that interferes with glioblastoma cell division and organelle assembly by delivering low-intensity alternating electric fields to the tumor. Investigators deliver the treatment through 4 transducer … (leggi tutto)